Dr. Kim reported that 95.5% of patients had complete epithelial healing at 3 days postoperatively, and all patients showed complete epithelial healing by 4 days. At 12 months, 4 eyes had evidence of grade 1 haze and 1 eye had grade 2 haze. At 12 months, 99.1% of patients had 20/20 or better uncorrected visual acuity. Nearly all patients showed progressively improving visual acuity from 3 weeks through the 2-month, 6-month and 12-month exams.
Refractive results were excellent and highly predictable. At 12 months, 98.5% of patients were within 0.5 D of the preoperative spherical equivalent target, 96.2% were within 0.5 D of the spherical refraction target and 94.8% were within 0.5 D of the cylindrical refraction target. Results were also extremely stable. Most patients, 97.8%, had a change in spherical equivalent of 0.5 D or less from 2 months postoperatively to 12 months after surgery.
While the outcomes from the Amaris instrument are highly positive, the instrument is not ideal for all patients, Dr. Kim noted. It is less useful in patients with abnormal or uneven epithelial thickness resulting from scarring due to prior procedures or corneal pathology. The study also did not attempt to evaluate high order aberrations or make direct comparisons with other surface ablation techniques.
“This study, like many others around the world, show that transepithelial PRK using the Amaris platform showed very good effectiveness, safety and predictability, faster epithelial healing, and less postoperative pain than we see in the literature for other types of refractive surgery,” Dr. Kim said. “It is a very useful alternative for the patient who wants faster healing and less postoperative pain.”
Subscribe to Ophthalmology Times to receive the latest clinical news and updates for ophthalmologists.